In a report published Friday, BMO Capital Markets analyst Joanne K. Wuensch reiterated an Outperform rating on CareFusion CFN and raised the price target to $41 from $38.
In the report, BMO Capital Markets noted, "We reiterate our Outperform rating on shares of CFN. The stock has run hot and heavy YTD, rising 31.5% versus the S&P 500's 14.4%. Some of the ascent, we believe, is associated with continued execution of the company's strategic plan, particularly operating margin expansion and anticipation that
the company will expand its footprint through acquisition (which we expect, although management appears to be sensitive to the strategic fit and price)".
CareFusion closed on Friday at $37.55.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in